Recent researched have shown spatial temporal heterogeneity among lung cancer, and the emergence of concurrent mutations such as MET amplification or other driver oncogene before or during pharmacologic intervention can also induce osimertinib resistance (18, 29, 41). The gene discussed is MET; the disease is lung cancer.